Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multiple-ascending dose study of RG-012 for the trearmet of Alport syndrome

Next Previous
X
Search
Trial Profile

A multiple-ascending dose study of RG-012 for the trearmet of Alport syndrome

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Nov 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lademirsen (Primary)
  • Indications Hereditary nephritis
  • Focus Adverse reactions

    • Most Recent Events

    • 06 Nov 2018 Status changed from active, no longer recruiting to completed, according to a Regulus Therapeutics media release.
    • 12 May 2017 Accordign to a Regulus (10 Q SEC filings http://files.shareholder.com/downloads/AMDA-14LKIJ/4455726230x0xS1628280-17-4992/1505512/filing.pdf) media release, this study was initiated in the 2016.
    • 12 May 2017 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top